| Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents G Middendorff, R Elsey, B Lounsbery, R Chadwell Journal of Oncology Pharmacy Practice 24 (5), 371-378, 2018 | 27 | 2018 |
| Utilizing tumor and plasma liquid biopsy in treatment decision making for an estrogen receptor-positive advanced breast cancer patient B Xu, A Krie, P De, C Williams, R Elsey, J Klein, B Leyland-Jones Cureus 9 (6), 2017 | 17 | 2017 |
| Down’s Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship N Dey, A Krie, J Klein, K Williams, A McMillan, R Elsey, Y Sun, C Williams, ... International Journal of Molecular Sciences 18 (6), 1218, 2017 | 11 | 2017 |
| Copper (I) halides inhibit olefin isomerized by-products from phosphine-based Grubbs’ metathesis catalysts in polar protic solvents MD Schulz, MBJ Atkinson, RJ Elsey, MM Thuo Transition Metal Chemistry 39, 763-767, 2014 | 6 | 2014 |
| A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers D Starks, L Rojas‐Espaillat, T Meissner, R Elsey, B Xu, M Koenen, S Feng, ... Cancer Medicine 12 (18), 18654-18665, 2023 | 3 | 2023 |
| QOPI Clinical Informatics: A digital platform to enable real-time quality reporting, clinical decision support, and rapid learning. CB Williams, K Karagoz, R Elsey, T Meißner, M Higashi, E Schadt, T Jun, ... Journal of Clinical Oncology 40 (16_suppl), e13545-e13545, 2022 | 1 | 2022 |
| Clinical outcomes between obese and non-obese breast and gynecological cancer patients with alterations in the PI3K/AKT/mTOR pathway D Kim, B Xu, R Elsey, T Meissner, C Williams Cancer Research 81 (13_Supplement), 1385-1385, 2021 | 1 | 2021 |
| Case report: 16-yr life history and genomic evolution of an ER+ HER2− breast cancer B Xu, A Amallraja, P Swaminathan, R Elsey, C Davis, S Theel, S Viet, ... Molecular Case Studies 6 (6), a005629, 2020 | 1 | 2020 |
| Genomic Considerations in the Treatment of Thyroid Carcinoma CJ Hattum, RJ Elsey, T Meissner, WC Spanos JCO Oncology Practice, OP. 24.00198, 2024 | | 2024 |
| Mutational signatures and their associations with social determinants of health P Swaminathan, MK Deaton, C Hattum, B Solomon, W Spanos, D Starks, ... Cancer Research 84 (6_Supplement), 6160-6160, 2024 | | 2024 |
| Differential gut microbiome alpha diversity in endometrial and ovarian carcinoma patients CT Finnicum, T Meissner, C Davis, S Viet, JL Petersen, MK Deaton, ... Cancer Research 84 (6_Supplement), 6204-6204, 2024 | | 2024 |
| Development/validation of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for cancer patients-continuous study Y Sun, T Meissner, R Elsey, C Hattum, C Williams Cancer Research 84 (6_Supplement), 2554-2554, 2024 | | 2024 |
| Avera/Sema4 oncology and analytics protocol (ASAP): Quantification of HER2 protein expression and activation status in gynecologic malignancies utilizing reverse-phase protein … C Williams, D Starks, L Rojas-Espaillat, R Elsey, T Meissner, J Davis, ... Gynecologic Oncology 176, S169-S170, 2023 | | 2023 |
| Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154) C Williams, D Starks, M Koenen, S Feng, T Meissner, R Elsey, ... Gynecologic Oncology 176, S229-S230, 2023 | | 2023 |
| Comprehensive molecular profiling and deep clinical annotation of electronic health records in patients with cancer: Implementation of the Avera/Sema4 oncology and analytics … C Williams, D Starks, L Rojas-Espaillat, T Meissner, R Elsey, T Jun, ... Gynecologic Oncology 176, S161-S162, 2023 | | 2023 |
| Use of CLIA accredited multi-omic platforms to correlate clinical significance of WES/WTS testing with functional protein/phosphoprotein drug target activity. R Elsey, T Meissner, C Mueller, B Corgiat, JB Davis, C Hattum, ... Journal of Clinical Oncology 41 (16_suppl), e15150-e15150, 2023 | | 2023 |
| Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study. MD Phan, PA El Tomb, T Khreis, T Meissner, R Elsey, B Xu, J Arshad, ... Journal of Clinical Oncology 41 (16_suppl), 2654-2654, 2023 | | 2023 |
| Evaluating the impact of a molecular tumor board in a community oncology center: Results from the Avera Cancer Institute's experience. R Elsey, T Meissner, Y Sun, C Hattum, HA McKean, BM Solomon, ... Journal of Clinical Oncology 41 (16_suppl), e13500-e13500, 2023 | | 2023 |
| Analysis of survival outcomes in patients with non–small-cell lung cancer with mutations in STK11/LKB1 receiving chemoimmunotherapy. D Kim, R Elsey, T Meissner, Y Sun, B Xu, C Hattum, BM Solomon, JH Lee, ... Journal of Clinical Oncology 41 (16_suppl), e15043-e15043, 2023 | | 2023 |
| Development/validation of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for cancer patients Y Sun, T Meissner, R Elsey, L Theisen, C Hattum, B Xu, J Lee, C Williams Cancer Research 83 (7_Supplement), 1057-1057, 2023 | | 2023 |
